Search clinical trials for: ASA404

Total 57 results

Cancer Research UK
Cancer Society Auckland

Completed

Study of DMXAA (Now Known as ASA404) in Solid Tumors (DMXAA)

Solid Tumors
Novartis Pharmaceuticals

Completed

An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

Japan
Novartis Pharmaceuticals

Terminated

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

Histologically-proven and Radiologically-confirmed Solid Tumors

Italy, New Zealand
Novartis Pharmaceuticals

Terminated

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

Metastatic Cancer With Impaired Renal Function | Metastatic Cancer With Normal Renal Function

Belgium
Novartis Pharmaceuticals

Completed

Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors

Advanced or Recurrent Solid Tumors

Japan
University of California, San Francisco
Novartis Pharmaceuticals

Withdrawn

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

Tumors

United States
Novartis Pharmaceuticals

Terminated

A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

Metastatic Cancer

United States
Ascletis Pharmaceuticals Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

Acne Vulgaris

China
Novartis Pharmaceuticals

Terminated

A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors

Advanced Solid Tumors

New Zealand
Novartis Pharmaceuticals

Terminated

Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor

Solid Tumors

United States
Ascletis Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris

Acne
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

Acne

China
Hoosier Cancer Research Network
Novartis Pharmaceuticals

Withdrawn

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

Urothelial Carcinoma
Kirilys Therapeutics Inc.

Active, not recruiting

Study of ASN004 in Patients With Advanced Solid Tumors (ASN004)

Solid Tumor

United States
Antisoma Research

Completed

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

Prostate Cancer

United States
Antisoma Research

Completed

Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma

Metastatic Renal Cell Carcinoma | Metastatic Malignant Melanoma

United Kingdom, New Zealand
Novartis Pharmaceuticals

Terminated

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer (ATTRACT-2)

Non-Small Cell Lung Cancer

United States, Germany, Belgium, Italy, France, Canada, Hungary, Poland, Switzerland, Spain
Novartis Pharmaceuticals

Terminated

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer (ATRACT-1)

Non-Small Cell Lung Cancer

United States, Greece, Hong Kong, Taiwan, Argentina, Germany, United Kingdom, Singapore, Italy, Spain, France, Korea, Republic of, Netherlands, Brazil, Canada, Turkey, China, New Zealand, Hungary, Poland, Australia, Japan, Israel, Bel... and more
Erasmus Medical Center
ISA Pharmaceuticals B.V.

Recruiting

Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 (HEB-PEP)

Chronic Hepatitis b

Netherlands
Clemson University
University of Alabama at Birmingham; National Institute on Aging (NIA); Penn...

Recruiting

Elucidating the Necessary Active Components of Training (ENACT)

Cognitive Impairment | Cognitive Change | Alzheimer Disease

United States
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

Infections, Papillomavirus

Belgium, United States
Swiss Group for Clinical Cancer Research

Completed

Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Lung Cancer

Switzerland
University of Nottingham
Nottingham University Hospitals NHS Trust

Not yet recruiting

Effect of Consuming Products Containing Rare Sugars Alongside Sucrose on Glycaemic Response in Healthy Adults

Glycaemic Response in Healthy Participants

United Kingdom
Novartis Pharmaceuticals

Terminated

A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies

Solid Tumor Malignancies

United States
Antisoma Research

Completed

Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
GlaxoSmithKline

Completed

Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years

Infections, Papillomavirus

Korea, Republic of
GlaxoSmithKline

Completed

A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Infections, Papillomavirus

Hong Kong
GlaxoSmithKline

Completed

Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Infections, Papillomavirus

Malaysia
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.

Infections, Papillomavirus

Taiwan, Spain, Germany, Colombia, France, Sweden, Australia, Korea, Republic of, Honduras, Czech Republic, Norway, Panama
GlaxoSmithKline

Completed

Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults

Infections, Papillomavirus

Canada, United States, Brazil
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18

Infections, Papillomavirus

Finland, Russian Federation, Denmark, Greece, Netherlands, Estonia
GlaxoSmithKline

Completed

A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females

Infections, Papillomavirus

China
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

Infections, Papillomavirus

Japan
National Institute for Control of Vaccine and Biologicals

Unknown

Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule (HPV-022 PRI)

Human Papillomavirus (HPV) Vaccine

Vietnam
GlaxoSmithKline

Completed

A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years

Infections, Papillomavirus

Korea, Republic of
GlaxoSmithKline

Completed

Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women

Infections, Papillomavirus

India
GlaxoSmithKline

Completed

Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

Infections, Papillomavirus
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects

Infections, Papillomavirus

Germany, Spain, France
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Recurrent Glioblastoma

China
Antisoma Research

Terminated

Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer

Breast Carcinoma

Russian Federation
GlaxoSmithKline

Terminated

A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.

Human Papillomavirus Infection Leading to Cervical Cancer

Philippines
GlaxoSmithKline

Completed

Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years

Infections, Papillomavirus

Netherlands
Washington University School of Medicine

Completed

Roux-en-Y Gastric Bypass and Weight Regain

Obesity

United States
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Infections, Papillomavirus

Canada, Denmark, Hungary, Sweden
GlaxoSmithKline

Completed

Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

Cervical Cancer | Precancerous Condition

Costa Rica
GlaxoSmithKline

Completed

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Infections, Papillomavirus

United States, Spain, Finland, Germany, Taiwan, Belgium, Philippines, Canada, Australia, United Kingdom, Thailand, Brazil, Italy, Mexico
GlaxoSmithKline

Completed

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

Herpes Simplex

United States, Australia, Spain, Romania, United Kingdom, Belgium, Canada, Estonia, France, Hungary, New Zealand, Sweden, Netherlands, Norway, Greece, Denmark, Iceland, Lithuania
National Cancer Institute (NCI)

Active, not recruiting

Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial

Human Papillomavirus-Related Cervical Carcinoma

Costa Rica
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.

Human Papillomavirus (HPV) Infection

Senegal, Tanzania
University of Illinois at Chicago
HiberCell, Inc.

Terminated

(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer (PM-01)

Pancreatic Cancer

United States

3

Subscribe